Current therapeutic strategies of anti-HER2 treatment in advanced breast cancer patients

被引：7

作者：

Huszno, Joanna ^{[1
,2
]}

Nowara, Elzbieta

机构：

[1] Maria Sklodowska Curie Mem Canc Ctr, Clin & Expt Oncol Dept, Gliwice, Poland

[2] Inst Oncol, Gliwice, Poland

来源：

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY | 2016年 / 20卷 / 01期

关键词：

breast cancer; HER2; overexpression; treatment strategy; clinical trials;

D O I：

10.5114/wo.2016.58495

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The HER2/neu (ERBB2) oncogene is amplified and/or overexpressed in approximately 20% of breast cancers, and is a strong prognostic factor for relapse and poor overall survival, particularly in node-positive patients. It is also an important predictor for response to trastuzumab, which has established efficacy against breast cancer with overexpression or amplification of the HER2 oncogene. Treatment with the anti-HER2 humanized monoclonal antibody - trastuzumab significantly improves progression-free and overall survival among patients with HER2-positive breast cancer. However, in most patients with HER2-positive metastatic breast cancer, the disease progresses occurred, what cause the need for new targeted therapies for advanced disease. In clinical trials, there are tested new drugs to improve the results of treatment for this group of patients. This paper presents new drugs introduced into clinical practice for treatment of advanced breast cancer, whose molecular target are receptors of the HER2 family. In addition, new therapeutic strategies and drugs that are currently in clinical researches are discussed.

引用

页码：1 / 7

页数：7

共 37 条

[1] Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy [J].

Awada, A. ;

Dirix, L. ;

Manso Sanchez, L. ;

Xu, B. ;

Luu, T. ;

Dieras, V. ;

Hershman, D. L. ;

Agrapart, V. ;

Ananthakrishnan, R. ;

Staroslawska, E. .

ANNALS OF ONCOLOGY, 2013, 24 (01) :109-116

[2] Herceptin® alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer:: Pivotal trials [J].

Baselga, J .

ONCOLOGY, 2001, 61 :14-21

[3] Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].

Baselga, J ;

Tripathy, D ;

Mendelsohn, J ;

Baughman, S ;

Benz, CC ;

Dantis, L ;

Sklarin, NT ;

Seidman, AD ;

Hudis, CA ;

Moore, J ;

Rosen, PP ;

Twaddell, T ;

Henderson, IC ;

Norton, L .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744

[4] Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy [J].

Baselga, Jose ;

Gelmon, Karen A. ;

Verma, Shailendra ;

Wardley, Andrew ;

Conte, PierFranco ;

Miles, David ;

Bianchi, Giulia ;

Cortes, Javier ;

McNally, Virginia A. ;

Ross, Graham A. ;

Fumoleau, Pierre ;

Gianni, Luca .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1138-1144

[5] A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer [J].

Berns, Katrien ;

Horlings, Hugo M. ;

Hennessy, Bryan T. ;

Madiredjo, Mandy ;

Hijmans, E. Marielle ;

Beelen, Karin ;

Linn, Sabine C. ;

Gonzalez-Angulo, Ana Maria ;

Stemke-Hale, Katherine ;

Hauptmann, Michael ;

Beijersbergen, Roderick L. ;

Mills, Gordon B. ;

de Vijver, Marc J. van ;

Bernards, Rene .

CANCER CELL, 2007, 12 (04) :395-402

[6]

BORG A, 1990, CANCER RES, V50, P4332

[7] Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer [J].

Burstein, Harold J. ;

Sun, Yan ;

Dirix, Luc Y. ;

Jiang, Zefei ;

Paridaens, Robert ;

Tan, Antoinette R. ;

Awada, Ahmad ;

Ranade, Anantbhushan ;

Jiao, Shunchang ;

Schwartz, Gary ;

Abbas, Richat ;

Powell, Christine ;

Turnbull, Kathleen ;

Vermette, Jennifer ;

Zacharchuk, Charles ;

Badwe, Rajendra .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) :1301-1307

[8] Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen [J].

Buzdar, Aman U. ;

Valero, Vicente ;

Ibrahim, Nuhad K. ;

Francis, Deborah ;

Broglio, Kristine R. ;

Theriault, Richard L. ;

Pusztai, Lajos ;

Green, Marjorie C. ;

Singletary, Sonja E. ;

Hunt, Kelly K. ;

Sahin, Aysegul A. ;

Esteva, Francisco ;

Symmans, William F. ;

Ewer, Michael S. ;

Buchholz, Thomas A. ;

Hortobagyi, Gabriel N. .

CLINICAL CANCER RESEARCH, 2007, 13 (01) :228-233

[9] Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial [J].

Buzdar, Aman U. ;

Suman, Vera J. ;

Meric-Bernstam, Funda ;

Leitch, A. Marilyn ;

Ellis, Matthew J. ;

Boughey, Judy C. ;

Unzeitig, Gary ;

Royce, Melanie ;

McCall, Linda M. ;

Ewer, Michael S. ;

Hunt, Kelly K. .

LANCET ONCOLOGY, 2013, 14 (13) :1317-1325

[10] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].

Cobleigh, MA ;

Vogel, CL ;

Tripathy, D ;

Robert, NJ ;

Scholl, S ;

Fehrenbacher, L ;

Wolter, JM ;

Paton, V ;

Shak, S ;

Lieberman, G ;

Slamon, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648

← 1 2 3 4 →